Precision oncology diagnostics: Myriad’s MyChoice gains FDA nod as partners co‑develop liquid and tissue tests

Myriad Genetics secured FDA approval for its MyChoice CDx as a companion diagnostic to stratify patients for GSK’s PARP inhibitor Zejula in advanced ovarian cancer, using BRCA sequencing plus a genomic instability score. The approval formalizes a tissue‑based HRD pathway for maintenance therapy. In parallel, Illumina and Labcorp expanded a precision oncology testing collaboration to explore co‑commercialization of Labcorp’s PGDx Elio Plasma Focus liquid biopsy with Illumina’s TruSight solid‑tumor panel, signaling coordinated efforts to offer matched plasma and tissue assays for therapy selection and monitoring.